Xencor (XNCR) Q2 Revenue Jumps 82%
Financial Performance: Xencor reported Q2 2025 revenue of $43.6 million, exceeding estimates by 93%, with a narrowed net loss of $(0.41) per share, reflecting strong milestone and royalty revenues from partnerships.
Clinical Advancements: The company continues to progress its clinical programs in oncology and autoimmune diseases, with several key drugs in various stages of testing, while maintaining a robust cash position of $663.8 million to support operations into 2028.
Trade with 70% Backtested Accuracy
Analyst Views on XNCR
About XNCR
About the author
Incyte reveals EU authorization for lymphoma treatment developed in partnership with Xencor
Approval of Minjuvi: The European Commission has approved Incyte's drug Minjuvi, in combination with lenalidomide and rituximab, as a late-line treatment for adults with relapsed or refractory follicular lymphoma.
Second Indication: This approval marks the second indication for Minjuvi in the EU, following its conditional approval for use in relapsed or refractory diffuse large B-cell lymphoma.
Xencor Extends Ultomiris Patent to 2028, Anticipates $100M to $120M in Additional Revenue
- Patent Extension: Xencor has been granted U.S. Patent 12,492,253 covering its Xtend™ Fc domain, extending the patent term to December 2028, which is approximately three years longer than the previous patent, ensuring low-single digit royalty income from Ultomiris.
- Potential Revenue Growth: Based on consensus sales forecasts, Xencor anticipates receiving an additional $100 million to $120 million in royalties during the extended patent term, which will support funding for its internal pipeline as it advances in clinical development.
- Strategic Partnership: OMERS has acquired royalties due to Xencor on global Ultomiris sales starting in 2026, with potential annual revenues of up to $35 million, enhancing the company's financial stability as excess royalties revert to Xencor.
- Technological Advantage: Xencor's Xtend antibody half-life extension technology provides new therapeutic mechanisms for its XmAb medicines, driving innovation in cancer and autoimmune disease treatments, aligning with its long-term value creation strategy.
JP Morgan Keeps Overweight Rating on Xencor, Reduces Price Target to $18
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
RBC Capital Reaffirms Outperform Rating for Xencor and Increases Price Target to $19
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Stories: The platform provides unique stories generated by Benzinga reporters, enhancing trading insights.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Winning Tools: Benzinga Pro equips traders with tools and information to improve their chances of success in the stock market.
Could Xencor's (XNCR) Preliminary Cancer Findings Indicate a New Advantage in Its Innovation Approach?
Xencor's Clinical Progress: Xencor, Inc. presented promising initial results from its Phase 1 study of XmAb819, a bispecific antibody targeting advanced clear cell renal cell carcinoma, highlighting the potential of its XmAb® 2+1 format for improved tumor targeting.
Investment Outlook: The company's future revenue projections suggest a significant increase by 2028, with a fair value estimate of $25.73 per share, indicating an 80% upside from its current price, though concerns remain about commercialization risks in competitive markets.
Xencor Unveils Preliminary Findings for XmAb819, a Novel ENPP3 x CD3 Bispecific T-Cell Engager Targeting Clear Cell Renal Cell Carcinoma
XmAb819 Clinical Trial Results: XmAb819, a bispecific antibody for advanced clear cell renal cell carcinoma (ccRCC), shows a 25% overall response rate and a well-tolerated safety profile in heavily pretreated patients during a Phase 1 study.
Dose Expansion and Future Plans: The first dose-expansion cohort has been selected, with ongoing dose escalation to determine the recommended Phase 3 dose, aiming to initiate a pivotal study in 2027.
Safety Profile and Adverse Events: The most common treatment-emergent adverse events were mild to moderate, including cytokine release syndrome and rash, with a few cases of Grade 3 events; no Grade 5 events were reported.
Webcast Announcement: Xencor will host a webcast to discuss the initial results, accessible through their website, with a recording available for 30 days.
Incyte reveals EU authorization for lymphoma treatment developed in partnership with Xencor
Approval of Minjuvi: The European Commission has approved Incyte's drug Minjuvi, in combination with lenalidomide and rituximab, as a late-line treatment for adults with relapsed or refractory follicular lymphoma.
Second Indication: This approval marks the second indication for Minjuvi in the EU, following its conditional approval for use in relapsed or refractory diffuse large B-cell lymphoma.
Xencor Extends Ultomiris Patent to 2028, Anticipates $100M to $120M in Additional Revenue
- Patent Extension: Xencor has been granted U.S. Patent 12,492,253 covering its Xtend™ Fc domain, extending the patent term to December 2028, which is approximately three years longer than the previous patent, ensuring low-single digit royalty income from Ultomiris.
- Potential Revenue Growth: Based on consensus sales forecasts, Xencor anticipates receiving an additional $100 million to $120 million in royalties during the extended patent term, which will support funding for its internal pipeline as it advances in clinical development.
- Strategic Partnership: OMERS has acquired royalties due to Xencor on global Ultomiris sales starting in 2026, with potential annual revenues of up to $35 million, enhancing the company's financial stability as excess royalties revert to Xencor.
- Technological Advantage: Xencor's Xtend antibody half-life extension technology provides new therapeutic mechanisms for its XmAb medicines, driving innovation in cancer and autoimmune disease treatments, aligning with its long-term value creation strategy.
JP Morgan Keeps Overweight Rating on Xencor, Reduces Price Target to $18
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
RBC Capital Reaffirms Outperform Rating for Xencor and Increases Price Target to $19
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Stories: The platform provides unique stories generated by Benzinga reporters, enhancing trading insights.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Winning Tools: Benzinga Pro equips traders with tools and information to improve their chances of success in the stock market.
Could Xencor's (XNCR) Preliminary Cancer Findings Indicate a New Advantage in Its Innovation Approach?
Xencor's Clinical Progress: Xencor, Inc. presented promising initial results from its Phase 1 study of XmAb819, a bispecific antibody targeting advanced clear cell renal cell carcinoma, highlighting the potential of its XmAb® 2+1 format for improved tumor targeting.
Investment Outlook: The company's future revenue projections suggest a significant increase by 2028, with a fair value estimate of $25.73 per share, indicating an 80% upside from its current price, though concerns remain about commercialization risks in competitive markets.
Xencor Unveils Preliminary Findings for XmAb819, a Novel ENPP3 x CD3 Bispecific T-Cell Engager Targeting Clear Cell Renal Cell Carcinoma
XmAb819 Clinical Trial Results: XmAb819, a bispecific antibody for advanced clear cell renal cell carcinoma (ccRCC), shows a 25% overall response rate and a well-tolerated safety profile in heavily pretreated patients during a Phase 1 study.
Dose Expansion and Future Plans: The first dose-expansion cohort has been selected, with ongoing dose escalation to determine the recommended Phase 3 dose, aiming to initiate a pivotal study in 2027.
Safety Profile and Adverse Events: The most common treatment-emergent adverse events were mild to moderate, including cytokine release syndrome and rash, with a few cases of Grade 3 events; no Grade 5 events were reported.
Webcast Announcement: Xencor will host a webcast to discuss the initial results, accessible through their website, with a recording available for 30 days.
